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ABSTRACT The favorable pharmacological profile exhibited by piracetam stimulated the synthesis of
related compounds potentially endowed with a higher nootropic potency. The antiamnesic and
procognitive activity of DM232 (unifiram), a new compound structurally related to piracetam, was
investigated. Mouse passive avoidance and rat Morris water maze and Social learning tests were
employed. DM232 (0.001–1mg kg1 i.p. – 0.01–0.1 1mg kg1 p.o.) prevented amnesia induced by
scopolamine (1.5mg kg1 i.p.), mecamylamine (20mg kg1 i.p.), baclofen (2mg kg1 i.p.), and clonidine
(0.125mg kg1 i.p.). Furthermore, The antiamnesic effect of the investigated compound was comparable
to that exerted by well-known nootropic drugs such as piracetam (30–100mg kg1 i.p.), aniracetam
(100mg kg1 p.o.), rolipram (30mg kg1 p.o.), and nicotine (5mg kg1 i.p). DM232 (0.1mg kg1 i.p.) was
also able to prevent amnesia induced by scopolamine (0.8mg kg1 i.p.) in the rat Morris watermaze test. In
the rat social learning test, DM232 (0.1mg kg1 i.p.) injected in adults rats reduced the duration of active
exploration of the familiar partner in the second session of the test. DM232, similarly to piracetam,
reduced the duration of hypnosis induced by pentobarbital. At the highest effective doses, the investigated
compound did not impair motor coordination (rota rod test), nor modified spontaneous (Animex). These
results indicate DM232 (unifiram) as a novel cognition enhancer, strictly related to piracetam-like
compounds, able to ameliorate memory impairment at doses about 1,000 times lower than the most active
available nootropic compounds. Drug Dev. Res. 56:23–32, 2002. c 2002 Wiley-Liss, Inc.
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INTRODUCTION
Nootropics (noos¼mind, tropein¼ towards) re-
present a heterogeneous compound group that in-
cludes the 2-pyrrolidinone derivatives piracetam,
oxiracetam, pramiracetam, etiracetam, aniracetam,
rolziracetam, and tenilsetam [Gouliaev and Senning,
1994]. The nootropic drugs facilitate learning and
memory or overcome natural or induced cognitive
impairments. The antiamnesic and memory-enhancing
properties of these compounds have been demon-
strated in various animal species and numerous
experimental paradigms [Gouliaev and Senning,
1994]. Furthermore, these compounds facilitate the
transcallosal, interhemispheric transfer of information
[Okuyama and Aihara, 1988] and enhance long-term
potentiation (LTP) in guinea-pig hippocampal slices
[Satoh et al., 1986; Pugliese et al., 1989]. The members
of this class present very low toxicity, no sedative or
stimulatory effects, and lack of serious side effects of
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psychostimulants [Heise, 1987]. This favorable phar-
macological profile stimulated the investigation of the
potential antiamnesic activity of nootropics in human
neurodegenerative pathologies. Nevertheless, results
from controlled clinical trials have questioned the
usefulness of nootropic compounds for treatment of
cognitive disorder in humans [Sarter, 1991], several
studies have demonstrated their usefulness for the
treatment of cognitive impairment in the elderly
[Vernon and Sorkin, 1991], in mild to moderate
dementia [Chouinard et al., 1983; Nicholson, 1990],
in Alzheimer’s disease [Croisile et al., 1993; Parnetti et
al., 1997], and for the treatment of cognitive deficit in
early Parkinsonism [Oepen et al., 1985].
Preliminary pharmacological studies reported
that 1,4-diazabicyclo[4.3.0]nonan-9-ones, structurally
related to piracetam, could represent a new class of
nootropic agents [Manetti et al., 2000a]. Among them,
the compound labeled DM232 (unifiram; Fig. 1)
appeared to be endowed with highest potency and
the best pharmacological profile. The aim of the
present study was to further investigate the capability
of DM232 to ameliorate impaired or unimpaired
memory functions in mice and rats.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (23–30 g), 4-month (400–
450 g), and 4-week (90–110 g) -old male Wistar rats and
70-day-old male hooded Long-Evans (average body
weight 270 g) from Morini (San Polo d’Enza, Italy)
were used. The mice were housed fifteen per cage
whereas the rats were individually housed in stainless-
steel cages. The cages were placed in the experimental
room 24 h before the test for adaptation. The animals
were fed a standard laboratory diet and tap water ad
libitum and kept at 23711C with a 12-h light/dark
cycle, light on at 7 a.m. The animals always had free
access to food and water. All experiments were carried
out according to the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by
the U.S. National Institutes of Health.
Passive-Avoidance Test
The test was performed according to the step-
through method described by Jarvik and Kopp [1967].
The apparatus consists of a two-compartment acrylic
box with a lighted compartment connected to a
darkened one by a guillotine door. Mice, as soon as
they entered the dark compartment, received a
punishing electrical shock (0.3mA, 1 sec). The latency
times for entering the dark compartment were
measured in the training test and after 24 h in the
retention test. The maximum entry latency allowed in
the training and retention sessions was, respectively, 60
and 180 s.
Spatial Reference Memory in the Morris Watermaze
Spatial learning was assessed in an open field
watermaze [Morris, 1984] consisting of a large circular
tank (diameter 1.5m; depth 0.6m) containing water at
24711C to a depth of 0.3m. The rats’ task was to
escape from the water by locating a hidden escape
platform (diameter 14 cm) submerged 1.5 cm below the
surface of the water. The water was made opaque by
the addition of 3 liters of semi-skimmed milk, which
prevents the animals from seeing the platform. The
pool was located on the floor in the center of an
acoustically insulated room (4 4) kept at a constant
temperature (24711C). Illumination inside the room,
containing various prominent cues, was 60 lux. The
swim paths taken by the animals in the pool were
monitored by a video camera mounted in the ceiling.
The resulting video signal was relayed to a video
recorder.
All rats were trained to find a hidden escape
platform, in a fixed location. They received 5 days of
training with 10 trial block per day. The platform was
located in the center of a chosen quadrant of the pool.
The rats were placed into the pool facing the side wall
at a position chosen randomly across trials and allowed
to swim until they found the platform, or for a
maximum of 60 sec. Any rat that failed to find the
platform in time was guided to its location by the
experimenter. The rats were then allowed to remain on
the platform for 20 sec. Rats were gently removed from
the platform and placed for 20 sec in a cage on the floor
of the same room before commencing the next trial. On
completion of behavioral testing, the rats were
returned to their home cages where they were briefly
warmed under a heating lamp. Ninety-six hours after
the last acquisition training, rats received again the
same behavioral procedure (retention/retraining test).
Fig. 1. The chemical structure of DM232 (unifiram): 4-(para-
Fluorobenzensulfonyl)-1,4-diazabicyclo[4.3.0]nonan-9-one.
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The latencies to reach the platform were
recorded blindly by means of a stopwatch. Data
reported for each day training were the means of ten
trials.
Social Learning Test
The social learning test was performed according
to Mondadori et al. [1992]. Male adult Wistar rats were
used throughout the experiments and juvenile males
were used as social stimuli. All the adult animals were
housed individually and placed in the testing room at
least 24 h before the experiment. On the day preceding
the experiment, adult rats were handled to become
familiar with the operator. Juvenile rats were housed
four per cage and brought into the testing room the
same day of the experiment. Experimental sessions
were always conducted between 10 a.m. and 2 p.m.
Each mature male rat was tested in its home-cage. The
first day of the experiment, a juvenile rat was
introduced into the adult male’s cage and the time
spent in social-investigatory behavior by the adult male
within a 5-min fixed interval was recorded. Social
investigatory behavior was defined as being proximally
oriented to the juvenile or in direct contact while
sniffing, following, nosing, grooming, or generally
inspecting any body surface of the juvenile. After
24 h, either the same juvenile or an unfamiliar one was
placed again into the mature male’s cage and social
investigatory behavior was recorded in a 5-min interval.
Data were reported as the difference between
exploration activity in the two sessions of the test.
Pentobarbital-Induced Hypnosis
After mice were treated with pentobarbital, their
loss of righting reflex was measured. The duration of
hypnosis was as the time to regain the righting reflex.
Hole Board Test
The hole board test utilizes a 40-cm-square plane
with 16 flush-mounted cylindrical holes (diameter
3 cm) distributed 4 by 4 in an equidistant, grid-like
manner. The mice were placed in the center of the
board one by one and left to move about freely for a
period of 5 min each. Two photoelectric beams,
crossing the plane from mid-point to mid-point of
opposite sides, thus dividing the plane into 4 equal
quadrants, automatically signaled the movement of
the animals on the surface of the plane. Miniature
photoelectric cells, in each of the 16 holes, recorded
the exploration of the holes (head plunging activity) by
the mice.
Rota Rod Test
The apparatus consists of a base platform and a
rotating rod of 3-cm diameter with a non-skid surface.
The rod was placed at a height of 15 cm from the base.
The rod, 30 cm in length, was divided into 5 equal
sections by 6 disks. Thus, up to 5 mice were tested
simultaneously on the apparatus, with a rod-rotation
speed of 16 r.p.m. The integrity of motor coordination
was assessed on the basis of the number of falls from
the rod in 30 s, according to Vaught et al. [1985].
Performance time was measured before and 15, 30,
and 45min after subcutaneous administration of the
drugs.
Spontaneous Activity Meter (Animex)
Locomotor activity in rats was quantified using an
Animex activity meter Type S (LKB, Farad, Sweden)
set to maximum sensitivity. Every movement of rats,
which were placed on the top of the Animex activity
meter, produced a signal due to variation in inductance
and capacity of the apparatus resonance circuit. Then
signals were automatically converted to numbers. On
the day of the experiment, the rats were treated and
then the cage, containing 3 rats, was put on the
measuring platform. Activity counts were made for
5min at 15-min intervals for 45min (total of 3 sessions)
starting immediately after injection of the drug.
Because of the arbitrary scale adopted to quantify
movements, drug-treated rats were always compared
with saline-treated ones.
Binding Studies
The binding profile of DM232 has been evaluated
under the auspices of NIMH Psychoactive Drug
Screening Program by Dr. B. Roth, CWR University,
Cleveland, OH. For more details on the investigated
receptors see: http://rothlab.cwru.edu/rothlabhome-
pag/default.htm .
Reagents and Compounds
The following drugs were used: DM232
(unifiram) prepared in the Department of Pharmaceu-
tical Sciences of University of the Florence according
to the method described by Manetti et al. [2000a];
scopolamine hydrobromide, piracetam, (7)baclofen
(Sigma); mecamylamine hydrochloride, clonidine hy-
drochloride, rolipram (RBI); nicotine hydrogentartrate
(Fluka); aniracetam (A. Menarini Industrie Farm-
aceutiche Riunite); pentobarbital (Sagatal).
Drugs were dissolved in isotonic (NaCl 0.9%)
saline solution, for i.p. injection, or dispersed in sodium
carboxymethyl cellulose 1%, for p.o. administration,
immediately before use. Drug concentrations were
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prepared so that the necessary dose could be
administered in a volume of 10ml kg1 by i.p. or p.o.
injection for mice and 3ml kg1 by i.p. administration
for rats.
Pharmacological Treatments
For memory disruption in the passive avoidance
test, mice were i.p. injected with amnesic drugs
(scopolamine, baclofen, mecamylamine, clonidine)
immediately after termination of the training session.
DM232, piracetam, aniracetam, rolipram, and nicotine
were injected 20 (i.p.) or 30 (p.o.) min before the
training session.
In the watermaze experiments, rats were i.p. injected
with DM232 and/or scopolamine 20 min before each
daily acquisition training. The day of the retention/
retraining rats were all i.p. injected with saline solution
20min before the test.
In the rat social learning test, DM232 and
piracetam were i.p. injected 20min before the first
session of the experiment.
Statistical Analysis
All experimental results are given as the means
7s.e.m. Analysis of variance (ANOVA), followed by
Fisher’s Protected Least Significant Difference (PLSD)
procedure for post-hoc comparison, was used to verify
the significance between two means in mouse beha-
vioral data. Mixed ANOVAs with pharmacological
treatments as a between-subjects variable and the
training days as a within-subjects variable and New-
man-Keuls multiple comparisons test were used for rat
behavioral experiments. Data were analysed with the
StatView software for the Macintosh (1992). P values
o0.05 were considered significant.
RESULTS
Effect of DM232 in the Mouse Passive
Avoidance Test
Pretreatment with DM232 prevented the amne-
sia induced by the administration of the antimuscarinic
drug scopolamine (1.5mg kg1 i.p.) after i.p. (0.001–
1mg kg1, Fig. 2A) and p.o. (0.01–0.1mg kg1, Fig. 2B)
injection in the mouse passive avoidance test. The
maximal antiamnesic effect of DM232 was obtained
with the dose of 0.01mg kg1 and maintained up to
1mg kg1. The DM232-induced antiamnesic effect was
of the same intensity of that exerted by the well-known
nootropic drugs piracetam (30mg kg1 i.p., Fig. 2A),
aniracetam (100mg kg1 p.o., Fig. 2B) and rolipram
(30mg kg1 p.o., Fig. 2B). Lower doses of DM232
(0.0001mg kg1 i.p., data not shown), piracetam
(10mg kg1 i.p., Fig. 2A), aniracetam (50mg kg1
p.o., Fig. 2B), and rolipram (10mg kg1 p.o., Fig. 2B)
were devoid of any ameliorative effect on scopolamine-
induced amnesia. At 1mg kg1 i.p., the entrance
latency value, in the retention session, of the DM232-
treated group was comparable to that produced by
control mice.
The administration of DM232 (0.01–0.1mg kg1
i.p.) antagonized the memory disruption produced by
mecamylamine (20mg kg1 i.p.), similarly to the
antiamnesic effect produced by nicotine (5mg kg1
i.p.) and piracetam (30mg kg1 i.p.). A dose 10-times
lower of DM232 was completely ineffective (Fig. 3).
DM232, at the doses of 0.01–0.1mg kg1 i.p., was
also able to prevent baclofen (2mg kg1 i.p.) induced
amnesia, whereas at the dose of 0.001mg kg1 i.p. was
devoid of any effect (Fig. 4). The DM232 prevention of
memory impairment was comparable to the effect
produced by piracetam (30mg kg1 i.p., Fig. 4).
Clonidine, at the dose of 0.125mg kg1 i.p.,
induced amnesia in the mouse passive avoidance test,
which was prevented by DM232 (0.01–0.1mg kg1 i.p.)
and piracetam (30mg kg1 i.p.), used as reference drug
(Fig. 5).
At active doses DM232 did not enhance the
entrance latency in unamnesic mice in comparison with
the control group (Fig. 2). Furthermore, there were no
differences observed in the various entrance latencies
of every group in the training session of the passive
avoidance test (Figs. 2–5).
Effect of DM232 in the Rat Morris Watermaze Test
All rats swam well in the pool and showed no
evidence of any sensorimotor impairment. As training
proceeded, the rats spent progressively less time at, or
near, the side walls and learned to use the platform as a
means of escape from the water. Consequently, all
animals showed a reduction in escape latencies and
path lengths with training. A significant reduction of
the average escape latencies of daily blocks during the
5 days of watermaze acquisition and the retention/
retraining was revealed (Fig. 6A). There was also a
significant main effect of treatments. The scopolamine
group rats were traveling significantly further before
finding the platform than the other three groups of rats
on day 5 (Fig. 6A) and on retention/retraining day (Fig.
6B). DM232 (0.1mg kg1 i.p.) was able to revert the
memory impairment induced by scopolamine on both
acquisition and retention/retraining days, whereas,
when administered alone, it was unable to ameliorate
unimpaired memory processes (Fig. 6).
No difference between the escape latencies of the
last day of acquisition and the retention/retraining test
was observed (Fig. 6).
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Effect of DM232 in the Rat Social Learning Test
Adults rats were treated with DM232 (0.01–
0.1mg kg1 i.p.) and piracetam (30mg kg1 i.p.), or
saline 20min before the first session of the test. In the
adult animals treated with DM232 (0.1mg kg1 i.p.),
the duration of active exploration of the familiar
partner at the second pairing at 24 h was shortened
in comparison with saline-treated rats (Fig. 7). No
curtailment was observed if an unknown partner was
presented (Fig. 7). At the dose of 0.01mg kg1 i.p.,
DM232 was ineffective. In the same experimental
conditions, a nootropic drug, such as piracetam,
reduced the time spent on exploratory behavior
Fig. 2. Dose-response curves of DM232 (ip) in comparison with piracetam (A) and DM-232 (po) in comparison with aniracetam and rolipram
(B) on amnesia induced by scopolamine (1.5mgkg1 ip) in mouse passive avoidance test. DM232, piracetam, aniracetam, and rolipram were
administered 20min (ip) and 30min (po) before training session while scopolamine was injected immediately after. The number of mice is inside
the column. nPo0.05 nnPo0.01 in comparison with scopolamine-treated mice.
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(Fig. 7). All drugs used did not modify the duration of
active exploration in the first session of the test in
comparison with saline-treated rats (data not shown).
Effect of DM232 on Pentobarbital-Induced Hypnosis
DM232 (0.1mg kg1 i.p.) significantly reduced
the total sleeping time (18.373.1nmin) induced by
60mg kg1 i.p. pentobarbital (27.576.3min), similarly
to the effect induced by 30mg kg1 i.p. piracetam
(12.575.3nmin). At the same doses, both drugs did not
modify the induction time of hypnosis (control:
3.871.6; DM232: 4.171.9; piracetam: 4.572.1min)
(nP o0.05 vs. pentobarbital).
Effect of DM232 on Motor Coordination and
Spontaneous Motility
It should be noted that DM232 elicited its
ameliorating effect on cognitive processes without
Fig. 3. Dose-response curve of DM232 (ip) in comparison with nicotine and piracetam on amnesia induced by mecamylamine (20mgkg1 ip)
in mouse passive avoidance test. DM232, nicotine, and piracetam were administered 20min before training session while mecamylamine was
injected immediately after. The number of mice is inside the column. nPo0.05 nnPo0.01 in comparison with mecamylamine-treated mice.
Fig. 4. Dose response curve of DM232 (ip) in comparison with
piracetam on amnesia induced by baclofen in mouse passive-
avoidance test. DM232 and piracetam were administered 20min
before training session while baclofen (2.0mgkg1 ip) was injected
immediately after. The number of mice is inside the column. nPo0.05
nnPo0.01, in comparison with baclofen-treated mice.
Fig. 5. Dose-response curves of DM232 (ip) in comparison with
piracetam on amnesia induced by clonidine in mouse passive
avoidance test. DM232 and piracetam were administered 20min
before training session while clonidine (0.125mg kg1 ip) was injected
immediately after. The number of mice is inside the column.
nnPo0.01 in comparison with clonidine-treated mice.
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changing animals’ gross behavior. No modification of
motor coordination was revealed by the mouse rota rod
test. DM232 (1–10mg kg1 i.p.) did not modify the
number of falls from the rotating rod in comparison
with saline-treated mice (Table 1). Furthermore,
mouse and rat spontaneous motility, as revealed,
respectively, by the rat Animex apparatus (Table 2)
and the mouse hole board test (data not shown) was
unmodified by DM232 administration (1mg kg1 i.p.)
in comparison with saline-treated animals.
Binding Profile of DM232
DM232, at 106 M, did not reveal any affinity
towards the most important central receptors, such as
Fig. 6. The effect of DM232 (0.1mgkg1 ip) on spatial reference
memory in the Morris water maze test. A: Effect of DM232 on
scopolamine (0.8mg kg1 ip)-induced impairment of rat acquisition.
Task acquisition is reflected as a decrease in escape latency. nPo0.05
in comparison with saline-treated rats. Vertical lines represent s.e.m.
B: Effect of DM232 on scopolamine-induced impairment in the
retention/retaining day. nPo0.05 in comparison with saline-treated
rats. Vertical lines represent s.e.m.
Fig. 7. Effect of D232 in comparison with piracetam in the rat social
learning test. DM232 and piracetam were administered 20min before
the first session. The number of rats is inside the column. nnPo0.01 in
comparison with saline-treated rats.
TABLE 1. Lack of Effect of DM-232 in Comparison With Piracetam in
the Mouse Rota Rod Testn
Endurance time on rota rod (s)
After treatment (min)
Dose Before
treatment
15 30 45
Saline 10ml kg1 ip 3.370.3 1.970.3 1.470.2 0.870.2
DM232 0.1ml kg1 ip 3.270.5 2.270.4 1.770.4 1.270.2
DM232 1.0mgkg1 ip 3.670.3 2.270.4 1.570.2 1.170.2
DM232 10mg kg1 ip 3.570.4 2.670.3 1.67 0.3 1.270.3
Piracetam 30mg kg1 ip 3.270.4 2.570.5 1.470.3 1.370.4
nEach value represents the mean of at least 10 mice.
TABLE 2. Lack of Effect of DM-232 in the Rat Animex Testn
Number of counts
after treatment
Dose 15min 30min 45min
Saline 10ml kg1 ip 691747 123721 44716
DM232 1mgkg1 ip 715756 115728 51711
nEach value represents the mean of at least 10 mice.
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serotoninergic, dopaminergic, muscarinic, nicotinic
adrenergic, glutamatergic, histaminergic, opiod, and
GABAergic (data not shown).
DISCUSSION
The present results describe the effects observed
with DM232 on experimentally impaired and unim-
paired memory processes in mice in rats. DM232
ameliorates cognitive processes not only by preventing
amnesia induced by pharmacological treatments in the
mouse passive avoidance and rat Morris watermaze
tests, but also by producing a procognitive activity in a
rat social learning task.
DM232 prevented amnesia induced by the
antimuscarinic drug scopolamine after i.p. and p.o.
administration and by the nicotinic antagonist meca-
mylamine in the mouse passive avoidance test.
Furthermore, DM232 was able to overcome the
impairment of the acquisition and retention/retraining
produced by scopolamine in the rat Morris watermaze
test. The lack of difference in the escape latencies
between the last day of acquisition and the retention/
retraining test led us to exclude the induction of state-
dependent effects [McGaugh, 1989; Overton, 1991].
That stimulation of the cholinergic system
improves cognitive processes has long been observed
[Coyle, 1995]. On the other hand, a blockade of the
cholinergic system produces a disruption of memory
functions. The administration of scopolamine, an
unselective muscarinic ACh receptor antagonist, re-
sults in impaired learning and memory in humans
[Frumier et al., 1976] and animals [Levin and Bowman
1986]. Animals treated with the M1 selective antagonist
pirenzepine and dicyclomine had impaired memory
processes in various paradigms in both mice and rats
[Caufield et al., 1983; Sala et al., 1991; Ghelardini et al.,
1997]. Furthermore, the administration of nicotinic
ACh receptor antagonists, such as mecamylamine,
produces a dose-dependent impairment of perfor-
mance in the passive avoidance test [Elrod and
Buccafusco, 1981].
It has been demonstrated, by microdialysis
studies, that DM232 is able to weakly increase ACh
release from rat parietal cortex [Manetti et al., 2000b],
a cerebral structure involved in the modulation of
cognitive processes [Bartus et al., 1982]. Therefore, the
potentiation of the cholinergic system induced by
DM232 could make it able to prevent amnesia induced
by an antimuscarinic drug as well as by the adminis-
tration of a nicotinic antagonist. The modulation of the
cholinergic system was also postulated as the mechan-
ism of action of the piracetam-like nootropic drugs
[Pepeu and Spignoli, 1989]. In particular, it has been
reported that piracetam might alter presynaptic
cholinergic functions, possibly by enhancing high-
affinity neuronal uptake of choline [Pedata et al.,
1984], but these data are still a matter of controversy
[Franklin et al., 1986]. Pilch and Mu¨ller [1988] showed
that piracetam elevated muscarinic receptor density in
the frontal cortex of aged but not of young mice.
Aniracetam was found to be able to increase the
acetylcholine content in the hippocampus and cerebral
cortex [Toide, 1989].
However, in binding studies, DM232 at 106 M
did not reveal any affinity towards not only muscarinic
and nicotinic receptors, but also for the most important
central receptors (data not shown) that might explain
the potentiation of the endogenous cholinergic system
induced by the investigated compound. The lack of
receptorial affinity is also a characteristic feature of the
nootropic compounds. These drugs, with the only
exception of nefiracetam, which shows high affinity for
the GABAA receptors, do not seem to act at any well-
characterized receptor system [Gouliaev and Senning,
1994]. Indeed, as already postulated for nootropic
compounds [Mondadori et al., 1991; Muller et al.,
1999], the DM232 effects on the cholinergic system
might be of secondary origin.
Amnesia can also be obtained by modulating
neurotransmitter systems different than the choliner-
gic. GABA is the main inhibitory neurotransmitter in
the brain and it plays an important role in learning and
memory. The activation of GABAA as well as GABAB
receptors has been reported to impair memory
performances [Jerusalinsky et al., 1994; Swartzwelder
et al., 1987]. The a2-agonists are known to exert a
variety of effects on the central nervous system. Central
depression usually accompanies therapeutic doses of
a2-agonists and impairment of cognitive functions is
also observed [Voronina et al., 1991; Genzoka-Papazova
et al., 1997].
DM232 was able to prevent amnesia induced by
the administration of baclofen and clonidine. Thus,
DM232 counteracts amnesia not only induced by
anticholinergic drugs, but also that obtained indepen-
dently from a cholinergic system blockade. DM232
ameliorates cognitive processes not only by preventing
amnesia induced by pharmacological treatments, but
also by producing a procognitive activity in a rat social
learning task in which adults rats with unimpaired
memory were used. DM232, as well as piracetam,
improved cognitive performance by prolonging the
time physiologically spent by rats to delete mnemonic
information.
DM232 did not show any procognitive activity in
the passive avoidance and Morris watermaze tests
when given alone. However, an improvement in
cognition of young animals that have no memory
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impairment is difficult to demonstrate. As a matter of
fact, not only DM232 but also well-known nootropic
drugs such as piracetam and aniracetam or cholinomi-
metics such as physostigmine and oxotremorine, do not
show any memory facilitation in unamnesic animals
[Gouliaev and Senning, 1994; Coyle, 1995].
In the first session, the latency to enter the dark
compartment of the light-dark box in the passive
avoidance test as well as the duration of the exploratory
activity in the social learning test and the escape
latency in the Morris watermaze test, were not
modified by the administration of DM232.
DM232 was also able to reduce the total sleeping
time induced by pentobarbital without modifying the
induction time of hypnosis. This effect was comparable
to that exerted by piracetam. The ability of nootropics
to reduce sleeping time was already observed in
humans. Hollister [1985] reported that piracetam
increases waking hours in elderly. This waking effect
would be beneficial for patients in which senile
dementia is associated with persistent sleepiness.
The amelioration of memory process induced by
DM232 is obtained without any induction of side
effects. DM232, at the highest effective doses, did not
impair motor coordination, as revealed by the rota rod
test, nor modify spontaneous motility, as indicated by
the Animex apparatus and the hole board test.
Furthermore, DM232, at a dose 1,000 times higher
than the minimal effective dose, is still devoid of any
alteration of behavioral parameters.
The present results provide evidence that DM232
is a new antiamnesic and procognitive compound for
which the belonging to the class of nootropic drugs can
be supposed. As a matter of fact, DM232 shows, not
only a chemical structural similarity with piracetam
[Manetti et al., 2000a], but also exhibits a pharmaco-
logical profile comparable to that of nootropics.
DM232 is, in fact, endowed with the main pharmaco-
logical properties of piracetam-like compounds: facil-
itation of memory processes, lack of toxicity and side
effects, lack of affinity towards the most important
central receptors. However, DM232 differs from
nootropics for its potency. Even if it exerts the same
pharmacological effects, DM232 is at least 1,000 times
more potent than the most active nootropic drugs, such
as oxiracetam, nefiracetam, etiracetam, and aniracetam
[Gouliaev and Senning, 1994].
In conclusion, these results indicate DM232 as a
novel cognition enhancer, strictly related to piracetam-
like compounds, but endowed with higher potency.
These observations, together with the lack of side effects
at a dose 1,000 times higher than the minimal active
one, permits considering DM232 a promising com-
pound for the treatment of human cognitive deficits.
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